{
    "ticker": "BTMD",
    "name": "BioTime, Inc.",
    "description": "BioTime, Inc. is a biotechnology company focused on the development and commercialization of innovative cell-based therapies for the treatment of age-related diseases and degenerative conditions. Established in 1990, BioTime is dedicated to advancing regenerative medicine through its proprietary technologies, which include pluripotent stem cells and their derivatives. The company's research encompasses a variety of applications, particularly in the fields of ophthalmology, orthopedics, and tissue engineering. BioTime's flagship products include therapeutic candidates for vision restoration and musculoskeletal repair, which leverage its expertise in stem cell biology and regenerative techniques. The company is committed to transforming healthcare with breakthrough therapies that can enhance the quality of life for patients suffering from severe and chronic conditions. With a robust pipeline of clinical programs and partnerships with leading research institutions, BioTime aims to be at the forefront of cell therapy development, creating impactful solutions for unmet medical needs. As part of its strategic vision, BioTime also seeks to educate and inform the public about the potential of stem cell therapies, advocating for regulatory frameworks that support innovation in regenerative medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Alameda, California, USA",
    "founded": "1990",
    "website": "https://www.biotimeinc.com",
    "ceo": "Shengfeng Yu",
    "social_media": {
        "twitter": "https://twitter.com/BioTimeInc",
        "linkedin": "https://www.linkedin.com/company/biotime-inc/"
    },
    "investor_relations": "https://ir.biotimeinc.com",
    "key_executives": [
        {
            "name": "Shengfeng Yu",
            "position": "CEO"
        },
        {
            "name": "Michael D. West",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "OpRegen",
                "Aneuploidy Testing"
            ]
        },
        {
            "category": "Stem Cell Technologies",
            "products": [
                "Pluripotent Stem Cells",
                "Differentiated Cell Products"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioTime, Inc. | Innovative Cell-Based Therapies for Age-Related Diseases",
        "meta_description": "Explore BioTime, Inc., a leader in biotechnology focused on regenerative medicine and stem cell therapies. Discover our innovative products and commitment to transforming healthcare.",
        "keywords": [
            "BioTime",
            "Biotechnology",
            "Stem Cell Therapy",
            "Regenerative Medicine",
            "OpRegen",
            "Age-Related Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is BioTime known for?",
            "answer": "BioTime is known for its innovative cell-based therapies and regenerative medicine technologies aimed at treating age-related diseases."
        },
        {
            "question": "Who is the CEO of BioTime?",
            "answer": "Shengfeng Yu is the CEO of BioTime, Inc."
        },
        {
            "question": "Where is BioTime headquartered?",
            "answer": "BioTime is headquartered in Alameda, California, USA."
        },
        {
            "question": "What are BioTime's main products?",
            "answer": "BioTime's main products include OpRegen and various pluripotent stem cell technologies."
        },
        {
            "question": "When was BioTime founded?",
            "answer": "BioTime was founded in 1990."
        }
    ],
    "competitors": [
        "CRSP",
        "REGN",
        "NVS",
        "GILD"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "VRTX",
        "VRTX"
    ]
}